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Background: Osteosarcoma (OS) is the most common type of solid bone cancer, with latent metastasis being a
typical mode of disease progression and a major contributor to poor prognosis. For this to occur, cells must resist
anoikis and be able to recapitulate tumorigenesis in a foreign microenvironment. Finding novel approaches to treat
osteosarcoma and target those cell subpopulations that possess the ability to resist anoikis and contribute to
metastatic disease is imperative. Here we investigate anchorage-independent (AI) cell growth as a model to better
characterize anoikis resistance in human osteosarcoma while using an expression profiling approach to identify and
test targetable signaling pathways.
Methods: Established human OS cell lines and patient-derived human OS cell isolates were subjected to growth in
either adherent or AI conditions using Ultra-Low Attachment plates in identical media conditions. Growth rate was
assessed using cell doubling times and chemoresistance was assessed by determining cell viability in response to a
serial dilution of either doxorubicin or cisplatin. Gene expression differences were examined using quantitative
reverse-transcription PCR and microarray with principal component and pathway analysis. In-vivo OS xenografts
were generated by either subcutaneous or intratibial injection of adherent or AI human OS cells into athymic nude
mice. Statistical significance was determined using student’s t-tests with significance set at α = 0.05.
Results: We show that AI growth results in a global gene expression profile change accompanied by significant
chemoresistance (up to 75 fold, p < 0.05). AI cells demonstrate alteration of key mediators of mesenchymal
differentiation (β-catenin, Runx2), stemness (Sox2), proliferation (c-myc, Akt), and epigenetic regulation (HDAC class
1). AI cells were equally tumorigenic as their adherent counterparts, but showed a significantly decreased rate of
growth in-vitro and in-vivo (p < 0.05). Treatment with the pan-histone deacetylase inhibitor vorinostat and the DNA
methyltransferase inhibitor 5-azacytidine mitigated AI growth, while 5-azacytidine sensitized anoikis-resistant cells to
doxorubicin (p < 0.05).
Conclusions: These data demonstrate remarkable plasticity in anoikis-resistant human osteosarcoma subpopulations
accompanied by a rapid development of chemoresistance and altered growth rates mirroring the early stages of
latent metastasis. Targeting epigenetic regulation of this process may be a viable therapeutic strategy.
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Osteosarcoma (OS) is the most common type of solid
bone cancer, mainly arising in children and young adults.
The long term survival for non-metastatic presentations
of OS is 70%, but recurrence continues to be associated
with an extremely poor prognosis [1]. The survival
rate for recurrent osteosarcoma is less than 30%, and
has remained relatively constant since the initiation
of doxorubicin-based chemotherapy regimens in the
1980’s [1]. Before routine use of chemotherapy, ampu-
tation was typically the treatment for patients with lo-
calized osteosarcoma, but the 5-year survival following
amputation was only 17% [2], confirming by natural
history that hematogeneous dissemination occurs early
in the disease process. Even today, with modern staging
methods, micrometastatic disease is not readily de-
tectable [3].
Anchorage-independent (AI) growth is an essential fea-
ture of malignancy [4] and metastatic progression [5].
The cancer cells must avoid anoikis, i.e., programmed
cell death in the absence of attachment to extracellular
matrix, for this to take place [6-8]. Anoikis is known to
occur through a Bcl-2-mediated intrinsic pathway [9,10]
or through an alternative extrinsic pathway in which
Apo1/Fas or TRAIL (tumor necrosis factor-related
apoptosis-inducing ligand) binding to cell-surface
death receptors triggers apoptosis [11]. AI growth has
been associated with disease progression and meta-
static potential in breast cancer, lung cancer, and mel-
anoma [7]. Anoikis resistance in epithelial-lines has
been associated with chemotherapy resistance and en-
hanced tumorigenicity [12-14], and increased expression
of markers – such as Oct4, Nanog, and Sox2 – that are
important in stem cell maintenance and development
[12,13,15,16]. Many of these markers are known to facili-
tate the oncogenic epithelial-to-mesenchymal transition
[17,18].
Much work using AI cell growth has been coupled
with manipulation of growth factor concentrations to
promote an undifferentiated and cancer stem cell-like
state, without paying close attention to processes driving
a cell’s ability to resist anoikis, and the phenotypic con-
sequences of those processes. Using a model of AI cell
growth, we sought to characterize the functional conse-
quences of anoikis resistance in human osteosarcoma,
particularly as they relate to the promotion of therapy
resistance and recurrence, while predicting and validating
novel therapies to target these cell subpopulations. We
demonstrate that AI growth of established and patient-
derived osteosarcoma cells alters the cellular growth rate
and promotes chemotherapy resistance, while AI induced
changes in growth rate persisted in-vivo. AI growth re-
sulted in a rapid change in the gene expression profile
including upregulation of the stem cell factor, sexdetermining region Y-box 2 (Sox2). c-Myc, β-catenin, Akt,
and histone deacetylases were confirmed to be a central
part of the AI growth molecular signature. Lastly, treat-
ment with the pan-histone deacetylase inhibitor vorinostat
and the DNA methyltransferase inhibitor 5-azacytidine
decreased AI cell growth, while 5-azacytidine sensitized
anoikis-resistant cells to doxorubicin. These data high-
light the importance of epigenetic regulation in anoikis




The human OS cell lines were derived from consent-
ing OS patients according to protocols approved by
the local ethics committee (IRB full name: Spectrum
Health Institutional Review Board; part of the Spectrum
Health Research Protection Program). Written informed
consent was obtained from the human research subjects
under an IRB-approved (IRB full name: Spectrum Health
Institutional Review Board), musculoskeletal tumor and
tissue acquisition protocol at Spectrum Health (2011-002).
Osteosarcoma cell lines 143B, MNNG/HOS (mHOS), and
MG-63 (ATCC) were cultured in Ultra-Low Attachment
plates (Corning) using DMEM or MEM (Gibco) supple-
mented with 1% L-glutamine, 1% penicillin/streptomycin,
and 10% fetal bovine serum (FBS) (Gibco). Cells iso-
lated from chemo-naïve and post-chemotherapy pa-
tient tumor samples were also grown in these Ultra-Low-
Attachment plates in the presence of MEMα (Gibco) with
1% L-glutamine, 1% penicillin/streptomycin, and 10% FBS.
Following 4-6 days of growth, the cells were passaged
using 0.05% trypsin (Gibco) dissociation and re-plated
in Ultra-Low Attachment plates. With each passage, vi-
abilities of single cells were assessed using trypan blue;
mean and standard error were calculated using Micro-
soft Excel. The determination of cell doublings per day
was calculated using the following formula:
Doublings=day ¼ log2 Final Cell Number  Starting Cell Numberð Þ
Number of Days
Statistical significance was determined using a two-
tailed two-sample t-test using R with significance set
at α = 0.05 [19].
Quantitative reverse transcription-PCR (qrt-PCR)
Total RNA was isolated using TRIzol reagent (Invitrogen).
Complementary DNA synthesis was performed using
500 ng RNA according to the instructions with the
High Capacity cDNA Reverse Transcription Kit (Invi-
trogen). Primer sequences for human genes of interest
are as follows (shown here, 5′ to 3′): Oct4 primers (F:
TAAGCTGCGGCCCTTGCTGC; R:CGGGCCTGCAC-
GAGGGTTTC), Sox2 primers (F:GGGGAAAGTAGT
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Axin2 primers (F:AAGCAAGCGATGAGTTTGCCT
GTG; R:ACAGCCAAGACAGTTCACAAGAGC), GA
PDH primers (F:AACTTTGGCATTGTGGAAGG; R:
GGATGCAGGGATGATGTTCT). Quantitative poly-
merase chain reactions were performed using SYBR
Select Mastermix (Applied Biosystems, Carlsbad, CA) in
10 μL reactions. Polymerase chain reaction was performed
according to the manufacturer’s instructions using a Ste-
pOnePlus cycler (Applied Biosystems). Cross-threshold
(CT) values were calculated using the version 2.1 soft-
ware (Applied Biosystems). Data were analyzed using
the 2-ΔΔCT method [20]. Data were presented as mean
and standard deviation using Microsoft Excel, with stat-
istical significance being determined using a two-tailed,
one-sample t-test with μ = 1 using R and significance
set at α = 0.05 [19].
Western blot analysis
Cells were washed with PBS and lysed on ice in lysis
buffer (RIPA lysis buffer) supplemented with complete
Protease Inhibitor Cocktail (Roche). Protein concentra-
tion was measured using the BCA assay (Pierce), and
20 μg of whole-cell lysate was run on a 10% SDS/poly-
acrylamide gel. The proteins were transferred onto a
nitrocellulose membrane, and membranes were probed
overnight at 4°C with the appropriate primary anti-
body; antibodies used were as follows: active β-catenin,
β-catenin, Runx2 (Cell Signaling Technologies); Ki67
(Spring Bioscience); and Actin (Millipore). Membranes were
then probed with a horseradish-peroxidase-conjugated sec-
ondary antibody for 1.5 hours at room temperature before
detection using an enhanced chemiluminescence (ECL)
detection system (Pierce). Because western blot analysis
was used to support microarray and cell growth findings,
images shown are representative of one independent
experiment for each cell line depicted.
Gene expression profiling and analysis
RNA was isolated as described above from established
(n = 3) and patient-derived (n = 7) human osteosarcoma
cell lines that were cultured in adherent or anchorage-
independent conditions. Total RNA was prepared separ-
ately from each individual cell line grown under adherent
or anchorage-independent conditions. Established cell
lines used included 143B, MNNG/HOS, and MG-63, while
patient-derived cell lines included MS124, MS124-2,
MS145, MS145-2, MS206, MS206-2, and MS088. Human
U133 Plus 2.0 arrays were performed at Clinical Reference
Laboratories (CRL, Lenexa, KS). Purified RNA (5 ng) was
used for amplification of cDNA (NuGen Ovation Pico
WTA System). cDNA was then fragmented and labeled
(NuGen Encore Biotin Module) and hybridized to Gene-
Chip Human Genome U133 Plus 2.0 Array (GeneChipHybridization, Wash and Stain Kit, Affymetrix). Standard
quality control metrics for percent present, scale factor,
and RNA quality were evaluated for each sample. Principal
component analysis (PCA) was completed using an R (ver
3.10) workflow using the BioConductor affy (ver 1.40.0)
package for RMA normalization and the “prcomp” func-
tion from the stats package. Two analysis approaches were
taken for differential expression analysis. Approach 1:
Affymetrix CEL files for both patient-derived and estab-
lished cell lines were processed with Affymetrix Expression
Console using MAS5.0 normalization for the differential
expressed top 300 gene list using a Welch’s T-test applied
to log base 2 transformed data. The top 300 genes were
imported into MetaCore from Thomson Reuters (version
6.19 build 65960) for pathway and network analysis. The
top two ranked pathways identified by the Analyze net-
work feature are shown in Additional file 1: Figure S1a
and b. The Shortest paths feature with length = 1 and
canonical pathways disabled was used for shortest path-
way analysis. The top 300 genes are supplied in Additional
file 2: Table S1, split into upregulated and downregulated
groups ordered by t-statistic value. No false discovery rate
correction was used because the intended purpose of the
gene list was for a discovery investigation of pathways util-
izing the GeneGo database. Additional file 1: Figure S1a
and b shows an interaction network captured using Meta-
Core derived from a significant gene list. The lines that
connect the gene symbols on the MetaCore image repre-
sent the direction of interaction and the type of inter-
action. The arrow points to the gene that is affected and
the type of interaction is indicated by the color of the line.
Lines with color red means inhibition, green means activa-
tion, and grey indicates an unspecified type of interaction.
The concentric circles with red centers show that the gene
was in the gene list and up regulated. The concentric
circles with blue indicates the gene was in the gene list
and was down regulated. The various gene symbols
represent classes of gene types. Generic binding genes
are blue “S” shaped, proteins are shown as three filled
blue circles overlapping, gold arrow shapes indicate
generic kinase genes and gold arrows with a hole in
the center indicate a generic protease. Transcription
factors are shown in red with two points on top and
three on the bottom. For the official legend refer to
https://ftp.genego.com/files/MC_legend.pdf. Approach 2:
Affymetrix CEL files for patient-derived cell lines were
imported into Bioconductor/R for processing via 3
normalization procedures (RMA, FRMA, and MAS5.0
background correction; affy package) and differential
expression analysis via paired t-test (limma package).
Significantly altered genes were identified as those
with p < 0.05 using a Benjamini & Hochberg false
discovery rate correction [21] across the ensemble of
normalization methods.
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Passaged cells (minimum 2 passages) were dissociated
and plated into 96-well Ultra Low Attachment plates
(Corning) and allowed to grow for 4 days before che-
motherapy exposure. Adherent cells were dissociated
around 70% confluence. Cells were plated into 96-well
white-walled plates (Greiner Bio-One) at 1 × 103 cells/
well and allowed to adhere for 24 hr before drug treat-
ments. The cells were then exposed to one concentra-
tion from a serial dilution of doxorubicin (0-10 μM; LC
Labs) or cisplatin (0-100 μM; Sigma) for 72 hr. Cell
viability was then determined using the CellTiter-Glo Lu-
minescent Cell Viability assay (Promega). Data were nor-
malized to an untreated control well and graphed using
GraphPad Prism software, and half maximal inhibitory
concentration (IC50) values were calculated from the
dose-response curve as the concentration of doxorubicin
or cisplatin that produced a 50% decrease in the mean
cell viability relative to untreated control wells. This is a
standard method to assess resistance to chemotherapy-
mediated toxicity in anchorage-independent cells as done
in the literature [12,13]. Data normality was determined
using the Shapiro-Wilk test. Statistical tests (two-tailed
paired t-test and wilcoxon signed-rank test) were performed
using R [19] with significance set at α= 0.05.
Vorinostat and 5-azacytidine treatment
Adherent cells were dissociated around 70% confluence.
Cells were plated into 96-well Ultra-Low Attachment plates
(Corning) or adherent tissue culture plates at 1 × 103 cells/
well in the presence of 2 μM Vorinostat (LC Labs), with di-
methyl sulfoxide (DMSO; Fischer) alone used as a control.
Cell viability was assessed after 4 days using the CellTiter-
Glo Luminescent Cell Viability assay (Promega). For che-
moresistance assays, cells were treated after 24 hours
with one concentration from a serial dilution of doxo-
rubicin, with cell viability being measured after an add-
itional 72 hours as described above. Pretreatment used
either 2 μM Vorinostat or DMSO alone for 12 days in ad-
herent conditions before plating the cells in 96-well Ultra
Low Attachment plates or adherent plates. 5-azacytidine
(5-azaC, Sigma) was dissolved in 50 mM sodium phosphate
(vehicle), and adherent OS cells were treated with 2 μM 5-
azaC or the same dilution of vehicle alone for 24 hours be-
fore being plated in 96-well Ultra-Low Attachment plates or
adherent tissue culture plates in the absence of 5-azaC or
vehicle. Cell viability or chemoresistance was then assessed
as described above. Data were graphed using GraphPad
Prism software, and two-tailed one-sample t-tests were
performed using R with significance set at α = 0.05 [19].
Orthotopic and non-orthotopic xenograft experiments
Following the approval of the research protocol by the
IACUC committee at the Van Andel Institute (IACUCprotocol #: 13-09-031 and XPA-14-02-004), cells sub-
jected to either AI or adherent growth were dissociated
into single-cell suspensions and were injected into the
flank of or intratibially into athymic nude mice. For
intratibial injection, mice were anesthetized via inhaled
isoflurane and cells were injected in a total volume of
20 μL through the tibial plateau. All efforts were made
to minimize suffering. Tumors were allowed to grow to
1500 mm3 or until euthanasia criteria were met. Tumor
volume calculations of intratibial tumors were done using
the formula V = (length × width2)/2 with the contralateral
leg as a control. Volumes were statistically compared at
each time point using a two-tailed two-sample t-test with
significance set at α = 0.05.Results
Anoikis-resistant OS cells robustly maintain viability and
exhibit sustained but down-regulated rates of growth
When plated in ultra-low attachment plates, subpopula-
tions of established and patient-derived human OS single
cell suspensions generated spherical colonies within 4 days
(Figure 1A-C). The viability of OS cells after continued
growth in AI conditions remained high, comparable to
that of adherent cells (data not shown). When we com-
pared the growth rate of cells cultured in adherent con-
ditions relative to those in AI conditions, cell doublings
per day was 2-3 times greater for the adherent cells
(Figure 1D). Prior studies have observed an increase in OS
cell death in response to AI growth, which we also ob-
served in some of our cell lines (data not shown) [22]. In
cells surviving AI growth, we observed decreased Ki67
protein levels, indicating that proliferation differences can
also contribute to these growth rate alterations (Figure 1E).
Thus, subpopulations of human OS cells are capable of
resisting anoikis and surviving AI growth, but at a lower
growth rate.Anoikis-resistant OS cells have increased resistance to
chemotherapy
To examine the effect of AI growth on the response of
OS cells to chemotherapy, we treated both AI and ad-
herent OS cells with increasing concentrations of main-
stay OS chemotherapies (doxorubicin and cisplatin) and
assessed cell viability after 72 hours. Across three estab-
lished OS cell lines and a patient-derived cell line, AI
cells showed a right shift in both dose-response curves
(Figure 2). An average IC50 was calculated for each group
(Table 1). In response to treatment with doxorubicin or
cisplatin, the established OS cell lines 143B and mHOS as
well as the patient-derived 206-2 OS cell line showed a
statistically significant increase in IC50 (Table 1). We were
not able to obtain an average IC50 for the MG-63 cell line
due to an inability to achieve a consistent 50% growth
Figure 1 Anoikis-resistant OS are viable and exhibit lower growth rates. A-C: Representative AI-grown OS cells generated from mHOS
(A), 143B (B), and a patient derived OS cell line, MS206-2 (C). D: Growth rates measured as cell doublings per day. Results shown are average ± standard
error. Asterisks indicate statistical significance (**p < 0.01, ***p < 0.001). E: Western blot analysis of 143B and MG-63 OS cells shows decreased Ki67 protein
levels in AI grown cells (P2 spheres) compared to adherent cells.
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chemotherapy tested.
Anoikis-resistant OS cells are molecularly distinct
We assessed gene expression differences that may be im-
portant for OS cell anoikis resistance using both qrt-PCR
and microarray gene expression profiling. Expression
of genes involved in developmental programs including
Sox2, Oct4, and Wnt signaling were increased in the
AI-grown cells relative to adherent cells (Figure 3A).
This finding was statistically significant for the mRNA ex-
pression of Sox2. The gene expression of established and
patient-derived human OS cells cultured under AI condi-
tions to at least the first passage was compared with that
of cells cultured in adherent conditions using gene expres-
sion profiling with principal component analysis (PCA).
There were clear differences in the molecular signatures
between adherent and AI cells among established andpatient-derived OS cells, although this was less obvious in
the established cell lines (Figure 3B). A likely explanation
is that the established OS cell lines used are clonally
evolved and chemically transformed versions of primary
tumor cells, whereas the patient-derived cell lines were
grown in culture briefly (<5 passages) prior to analysis.
Shortest pathway analysis of the top 300 differentially
expressed genes confirmed significant alteration of Runx2,
class I HDACs, and Akt (Figure 3C). GeneGo de-novo
network generation identified convergence on Wnt/β-
catenin, c-myc, and alpha family G-proteins in the mo-
lecular signature of AI growth (Additional file 1: Figure
S1a and b). These findings pertaining to Runx2 and Wnt/
β-catenin signaling are supported through western blot
analysis (Additional file 1: Figure S1c). We identified 19
genes that passed false discovery with a corrected p-value
less than 0.05 (Table 2). Upregulated genes included
those involved in the DNA repair, oncogenic signaling,
Figure 2 Anoikis-resistant OS cells show resistance to standard OS chemotherapies. Dose-response curves for cells grown under AI or
adherent conditions treated with doxorubicin (top panel) or cisplatin (bottom panel) in a set of serial dilutions for 72 hours. Cell viability was
determined as a percentage of the untreated control (0 μM doxorubicin or cisplatin).
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those specific to mesenchymal lineages [23-26]. Downregu-
lated genes were involved in processes such as proliferation
and tumor suppressive functions [27,28]. These results
suggest that anoikis-resistant OS cells capable of AI growth
have expression changes in key genes that are necessary
for cell growth and survival under these conditions.Anoikis-resistant OS cells initiate tumors equal to adherent
OS cells in both orthotopic and non-orthotopic in-vivo
xenograft models, but maintain a lower growth rate
When AI and adherent grown human OS cells were
injected into athymic nude mice, both initiated tumors
at similarly low cell concentrations (Table 3). This was
despite our previous finding that AI OS cells had a lower
growth rate than adherent cells. This observation was
confirmed in both subcutaneous (non-orthotopic) and
intratibial (orthotopic) xenograft models. However, cellTable 1 72 hr IC50 for AI and adherent OS cells in the presenc
Doxorubicin
Cell type Mean IC50 (uM)
MS206-2 Adherent 0.062 ± 0.01
AI 1.79 ± 0.4
143B Adherent 0.025 ± 0.01
AI 0.31 ± 0.1
mHOS Adherent 0.085 ± 0.013
AI 2.97 ± 1.9
MG-63 Adherent 0.13 ± 0.06
AI >50% survival
^Indicates p < 0.05 (two-tailed two-sample t-test).
*Indicates p < 0.05 (wilcoxon signed-rank test).
#Indicates >50% cell viability after treatment, so we could not calculate an IC50.concentrations as low as 10,000 cells formed tumors intra-
tibially, as opposed to a threshold of 100,000 subcutane-
ously. These results indicate that anoikis-resistant OS cell
subpopulations have a tumorigenic capability similar to
that of their adherent counterparts, and that the intratibial
microenvironment may be a favorable setting for osteosar-
coma tumor formation.
To validate whether this alteration in growth rate would
hold true in an in-vivo setting, 2×105 AI and adherent
mHOS cells were injected intratibially into athymic nude
mice. Although no differences were noted in tumor initi-
ation rates, there were significant differences in the growth
rates once tumors were detected. The tumors derived from
AI-grown cells grew more slowly than those from adherent
cells (Figure 4). AI-grown patient-derived MS206-2 cells
also grew more slowly, although the results were not
statistically significant. These results indicate that the
slow-growth phenotype of cultured OS cells grown under
AI conditions is maintained in-vivo.e of doxorubicin or cisplatin
Cisplatin
Fold change Mean IC50 (uM) Fold change
28.8^ 4.38 ± 0.98 5.7^
25.2 ± 6.9
13* 1.97 ± 0.19 1.9*
3.12 ± 0.10
35* 3.10 ± 0.53 6.9*
21.4 ± 10.
>75# 2.68 ± 1.6 6.2*
16.9 ± 5.4
Figure 3 Anoikis-resistant OS cells demonstrate distinct patterns of altered gene expression. A: mRNA expression of the target genes
Oct4, Axin2, and Sox2 in AI-grown OS cells after the second passage (p2) was determined using qrt-PCR normalized to adherent cells. Asterisks
indicate statistical significance (**p < 0.01). B: Principal component analysis of gene expression using microarray. Gene expression differences
resulted in clustering of the adherent cells (squares) compared to the AI cells (triangles). This was more apparent for the patient-derived OS cells
than the established OS cell lines. Blue color indicates established OS cell line, green color indicates pre-chemotherapy patient-derived OS cell
line, red color indicates post-chemotherapy patient-derived OS cell line, black color indicates pulmonary metastasis patient-derived OS cell line,
dotted lines connect paired AI/adherent samples. C: Shortest pathway analysis of the top 300 differentially expressed genes identifies class I
HDACs, Runx2, and Akt as central contributors.
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Table 2 Significantly altered genes in AI OS cells
compared to adherent OS cells
Upregulated genes Downregulated genes
Gene name Fold increase Gene name Fold decrease
SOX5 11.30 CCBE1 7.81
PTPRE 5.59 MGLL 7.41
PARP14 3.15 CTGF 6.73
ZNF697 3.09 ABI3BP 5.76
SHC2 3.04 ANXA1 5.50
RUNX2 3.00 DDAH1 5.36
CHST2 2.45 CRIM1 3.66
MTHFSD 2.42 TRNP1 3.64
SH3BP2 2.34 KRT7 3.13
FHL2 2.92
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anchorage-independent growth and sensitize to
doxorubicin
The maintenance of phenotypic characteristics of AI-grown
OS cells raises the question of possible epigenetic modifica-
tions that allow for cell growth and survival under such
conditions. Indeed, our observation of c-myc, Akt, β-
catenin, and class I HDACs as key components in AI
growth strengthens this. Histone deacetylases (HDACs)
in many cases are a necessary component of c-myc signal-
ing, and targeted inhibition of HDACs can decrease growth
in c-myc overexpressing tumors [29-31]. Treatment of OS
cells with 5-azaC induced expression of PTEN, an inhibitor
of the PI3K/Akt pathway, while studies in pancreatic cancerTable 3 Proportion of mice that formed tumors after
xenotransplantation of AI or adherent OS cells
Number of cells injected
1 × 104 1 × 105 5 × 105
Subcutaneous
mHOS
Adherent 0/5 3/5 4/5
AI 0/5 3/5 3/5
143B
Adherent 0/5 1/5 4/5
AI 1/5 3/5 5/5
Intratibial
mHOS
Adherent 6/7 7/7 7/7
AI 5/7 6/7 7/7
143B
Adherent 5/7 7/7 6/7
AI 7/7 7/7 6/7demonstrate that 5-azaC treatment reduces proliferation of
pancreatic cancer cells through inhibition of Wnt/β-catenin
signaling and its downstream target c-myc [32,33]. This lit-
erature provides support for HDAC inhibitors and 5-azaC
in being able to target a very similar spectrum of signaling
pathways that we identified as being altered in anoikis-
resistant OS cells. Therefore, we sought to determine the
effects on OS cell growth, survival, and the response to
doxorubicin under AI conditions of the pan-HDAC inhibi-
tor vorinostat and the DNA methyltransferase inhibitor
5-azaC. AI-grown cells in the presence of 2 μM vorinostat
showed a statistically significant decrease in growth after
4 days as relative to DMSO-only controls (Figure 5A, B).
We next tested the pretreatment of adherent OS cells with
vorinostat and examined their ability to subsequently
undergo AI growth. We pretreated adherent OS cells
for 12 days with either 2 μM vorinostat or DMSO alone
before placing them in ultra-low attachment plates in
the absence of drug. Pretreatment with vorinostat de-
creased the ability of those cells to grow in AI conditions
(Figure 5C, D). Neither direct treatment nor pretreatment
with vorinostat sensitized AI OS cells to doxorubicin (data
not shown). Treatment of adherent mHOS cells with vori-
nostat similarly decreased cell growth (Additional file 3:
Figure S2a). However, vorinostat pretreatment trended to-
wards stimulating adherent cell growth, although this was
not statistically significant (Additional file 3: Figure S2a).
These results suggest that both direct treatment and
prolonged pretreatment with pan-HDAC inhibitors such
as vorinostat can effectively mitigate OS cell anoikis
resistance.
We next tested the effect of 5-azaC treatment on OS
cell growth and the response to doxorubicin under AI
conditions. We treated adherent mHOS cells with 2 μM
5-azaC or vehicle alone for 24 hours before plating in
ultra-low attachment plates in the absence of drug. Treat-
ment with 5-azaC decreased the ability of the mHOS cells
to grow and survive in AI conditions (Figure 6A, B).
Treatment with 5-azaC also resulted in a left-shift in the
72 hr dose-response curve of AI mHOS cells to doxorubi-
cin, indicating that these cells were more sensitive to
doxorubicin-mediated toxicity (Figure 6C). This was
reflected in a statistically significant decrease in the 72 hr
doxorubicin IC50 of 5-azaC treated AI cells compared to
vehicle treated cells (Figure 6D). Treatment of adherent
mHOS cells with 5-azaC trended towards inhibiting cell
growth, although this was not statistically significant after
the same number of controlled replicates (Additional file
3: Figure S2b). However, no clear difference in the re-
sponse to doxorubicin was observed in adherent cells
treated with 5-azaC (Additional file 3: Figure S2b). These
results suggest that 5-azaC treatment can effectively in-
hibit the growth of anoikis-resistant OS cells while simul-
taneously sensitizing them to chemotherapy.
Figure 4 Altered growth rates of anoikis-resistant AI-grown cells are maintained in-vivo. mHOS (A) and MS206-2 (B) cells were under AI
(red) and adherent conditions (blue) and were injected intratibially into athymic nude mice. Data shown are trend lines fit to the growth data,
with standard deviations for the average tumor volume for that time point. Asterisks indicate statistical significance (**p < 0.01).
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The goal of our work was to use gene expression analysis
to predict and test targeted therapies to mitigate aspects
of OS anoikis resistance. Many of the alterations we no-
ticed on expression profiling can be regulated through
epigenetic modifiers, raising the potential for the use
of existing FDA-approved epigenetic therapies to tar-
get anoikis-resistant OS cells. Proliferation of c-mycFigure 5 Vorinostat treatment and preconditioning inhibits anchorag
either 2 μM vorinostat or DMSO alone and allowed to grow for 4 days
spheres (A), and resulted in a statistically significant decrease in cell via
with either 2 μM vorinostat or DMSO alone and subsequently plated an
drug. Vorinostat pretreatment decreased the number of spheres (C) and
indicate statistical significance (*p < 0.05, ***p < 0.001).overexpressing lymphomas is reduced by HDAC inhib-
ition, and it has been demonstrated in osteosarcoma cells
that chromatin-modifying drugs such as vorinostat can in-
crease miRNA expression that leads to decreased c-myc
protein and induction of apoptosis [31,34]. 5-azaC treat-
ment inhibits proliferation of pancreatic cancer cells
through suppression of β-catenin/c-myc, while studies in
OS cells show that 5-azaC treatment increases expressione-independent OS cell growth. A/B: mHOS cells were treated with
in AI conditions. Vorinostat treatment decreased the number of
bility (B). C/D: Adherent mHOS cells were pretreated for 12 days
d allowed to grow for 4 days in AI conditions in the absence of
resulted in a significant decrease in cell viability (D). Asterisks
Figure 6 5-azaC treatment inhibits anchorage-independent OS cell growth while sensitizing to doxorubicin. A/B: Adherent mHOS cells
were treated with either 2 μM 5-azaC or vehicle alone for 24 hours before being plated in AI conditions in the absence of drug and allowed to
grow for 4 days. 5-azaC treatment decreased the cells ability to form spheres (A) and resulted in a significant decrease in cell viability (B). C/D:
Adherent mHOS cells were treated with either 2 μM 5-azaC or vehicle alone for 24 hours before being plated in AI conditions in the absence of
drug. 24 hours later the cells were treated with one concentration from a serial dilution of doxorubicin, with cell viability being measured after an
additional 72 hours. 5-azaC treatment resulted in a left-shift in the doxorubicin dose-response curve (C) and a significant decrease in the percent
IC50 relative to vehicle alone (D). Asterisks indicate statistical significance (*p < 0.05).
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sion profiling identified c-myc, β-catenin, Akt and class I
HDACs as important contributors to AI growth, thus
strengthening the rationale for the use of HDAC inhibi-
tors and 5-azaC in targeting these cell subpopulations. We
found that treatment with the HDAC inhibitor vorinostat
resulted in decreased AI cell growth. Additionally, pre-
treatment of adherent cells with vorinostat inhibited their
ability to subsequently grow in AI conditions. More work
is needed to determine which HDACs are involved, as well
as the specific histone acetylation changes taking place
that are important for anchorage-independent growth and
anoikis resistance. We also found that treatment with
5-azaC reduced AI cell growth and sensitized anoikis-
resistant cells to doxorubicin-mediated toxicity. The abil-
ity of 5-azaC to sensitize cancer cells to chemotherapy has
been observed, particularly in ovarian cancer [35]. Add-
itionally, 5-azaC has been shown to inhibit the Wnt/β-
catenin signaling pathway, an important contributor to
chemoresistance in human OS [33,36,37]. Future stud-
ies include examining changes in levels of DNA methyl-
transferases as well as determining important genomic
loci of DNA methylation in anoikis-resistant OS cells.
In-vivo assessment of the efficacy of vorinostat and 5-azaC
in OS xenografts will also be an area of future study.
Intuitively, acquired chemotherapy resistance to anti-
proliferative agents can be greatly affected by the rate of
cell division. We noticed that OS cells exhibit a decreasedgrowth rate under AI conditions. Indeed, the literature
supports mechanisms of altered growth rate in response
to AI growth that involve changes in key cell cycle regula-
tors such as cyclin D1 [38]. Another study in ovarian
cancer found that not all cells respond to AI growth with
cell cycle arrest, suggesting heterogenous and complex up-
stream molecular mechanisms [39]. Although more work is
required to define the specific mechanism for this growth
alteration, we found a variety of candidate mechanisms that
would also account for rapid acquisition of chemoresistance
beyond a decreased growth rate. We observed increased
expression of Sox2 in response to AI growth, which is
essential for self-renewal and tumorigenicity in OS tumor-
initiating cells [40]. Sox2 has also been implicated in con-
veying chemoresistance to cancer stem cell-like cells in
other cancers through ABCG2 expression levels [41]. Com-
parison of the gene expression profiles of AI and adherent
OS cells from freshly harvested patient tumors confirms a
common adaptation process underlying resistance to anoi-
kis and chemotherapy. Unbiased molecular pathway ana-
lysis of the top 300 differentially expressed genes identified
consistent signaling convergence on Wnt signaling, Runx2,
c-myc, and components of histone modification. Aberrant
Wnt signaling contributes to OS tumorigenesis, and in-
hibition of Wnt signaling effectively sensitizes OS cells to
chemotherapy [36,37,42]. c-myc overexpression is trans-
formative to bone marrow stromal cells and conveys inva-
sive properties to OS cells and resistance to cisplatin in
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events that are mediated by c-myc require functioning
HDACs [29,30]. Furthermore, increased expression of
Runx2 can suppress proliferation and chemosensitivity of
OS cells and has been shown to inhibit p53-dependent
apoptosis together with HDACs in response to DNA dam-
age [46-48]. Taken together, these pathways represent can-
didate contributors to the chemoresistance of anchorage-
independent human OS cells observed in our study beyond
altered cell growth. It is worth noting that the expression
profile of the chemically transformed, highly clonal estab-
lished OS cells showed less dramatic changes in the
anoikis-resistant gene signature. There was marked agree-
ment between the findings of the pathway analysis and the
individual differentially expressed genes identified, par-
ticularly as they relate to overall processes such as cell
growth and oncogenic signaling. In fact, Runx2 was identi-
fied in both analyses as a significant contributor to OS
anchorage-independent growth. Future work will include
interrogation of the pathway and gene alterations identi-
fied to determine their specific contributions towards the
phenotypic consequences of OS anoikis resistance.
We found that adherent and AI-grown OS cells were
equally tumorigenic in subcutaneous and intratibial set-
tings; the latter is arguably more similar to the osteosar-
coma tumor microenvironment. Prior work shows that
AI-grown OS cells are more capable of tumor initiation,
and the reasons for this difference are unclear [12,14].
Though we were unable to demonstrate a greater tumor-
initiating potential, cells cultivated in AI conditions main-
tain their decreased growth rate relative to adherent OS
cells in-vivo. It will be important in future studies to
examine metastatic rates between adherent and AI grown
OS cells. These data indicate that the phenotypic behavior
of AI-grown cells is not a transient finding.
The cultivation of human osteosarcoma cells through
anchorage-independent growth alters the growth rate,
promotes chemotherapy resistance, and produces a
distinct molecular signature both in-vitro and in-vivo. We
show that acquisition of anoikis resistance in human os-
teosarcoma subpopulations through anchorage-independent
growth results in a rapid development of chemoresis-
tance and altered growth rate, mirroring the early stages
of latent metastasis. Targeting epigenetic regulation of this
process may be a viable therapeutic strategy.
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Additional file 1: Figure S1. Genego and shortest pathway analysis of
AI and adherent OS cells. A: Genego molecular signature identifies Wnt/
β-catenin and the G-protein alpha family as significant nodes in AI OS cell
growth. B: GeneGO molecular pathway analysis shows significant convergence
on c-Myc in the AI expression signature. C: Support for altered Runx2 and
Wnt/β-catenin signaling through western blot analysis of adherent and
anoikis-resistant (p2 sphere) mHOS and MG-63 human OS cells.Additional file 2: Table S1. Top 300 gene list by GeneGo analysis.
Additional file 3: Figure S2. Vorinostat and 5-azaC treatment of adherent
OS cells. A: mHOS cells were treated with either 2 μM vorinostat or DMSO
alone and allowed to grow for 4 days in adherent conditions, which resulted
in a statistically significant decrease in cell viability (left panel). Adherent
mHOS cells were pretreated for 12 days with either 2 μM vorinostat or DMSO
alone and subsequently plated and allowed to grow for 4 days in adherent
conditions in the absence of drug. Vorinostat pretreatment trended towards
stimulating adherent OS cell growth, although this was not statistically
significant (right panel). B: Adherent mHOS cells were treated with either
2 μM 5-azaC or vehicle alone for 24 hours before being plated in adherent
conditions in the absence of drug and allowed to grow for 4 days.
5-azaC trended towards inhibiting cell growth, although this was not
statistically significant after the same number of controlled replicates
(left panel). Adherent mHOS cells were treated with either 2 μM 5-azaC
or vehicle alone for 24 hours before being plated in adherent conditions in
the absence of drug. 24 hours later the cells were treated with one
concentration from a serial dilution of doxorubicin, with cell viability
being measured after an additional 72 hours. 5-azaC treatment did not alter
the doxorubicin dose-response curve (middle panel), and there was no
significant difference in the percent IC50 relative to vehicle alone (right panel).
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